Mineralys Therapeutics, Inc. (MLYS) has released an update to notify the public and investors about an entry into a material definitive agreement.
Mineralys Therapeutics, Inc. has initiated a private placement to raise $120 million by selling shares and pre-funded warrants. The proceeds are set to advance the development of their drug lorundrostat, and to support general corporate functions, with enough funds to operate into 2026. This placement, which adheres to Nasdaq rules, includes provisions limiting individual ownership to prevent excessive concentration of control. The company has also committed to registering the securities for resale, ensuring compliance with SEC regulations and providing liquidity for investors. The transaction, reserved for accredited investors and avoiding public offering, reinforces the company’s financial stability and ongoing research endeavors.
For further insights into MLYS stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
